General information

Selection criteria

Cohorts

Expansion cohort: stage III

Collaboration

Available compounds per July 2021

Drug Target genes
Abemaciclib CCND1, CCND3, CDK4, CDK6, CCND2, CCND1 3’UTR
Alectinib ALK
Alpelisib PIK3CA, PIK3R1/2, PTEN, AKT, TSC1/2
Atezolizumab + bevacizumab TMB-H / HML – ≥ 16 mut/Mb
Axitinib KDR, FLT4
Crizotinib ALK, MET, MST1R, ROS1
Dabrafenib BRAF V600
Dabrafenib + trametinib BRAF V600
Dacomitinib EGFR, HER2, HER4
Erlotinib EGFR
Entrectinib ROS1
Lenvatinib FGFR1, FGFR2, FGFR3, FGFR4
Lorlatinib ALK, ROS1
Nilotinib KIT, ABL1, PDGFRa, PDGFRb
Nivolumab MSI-H
Nivolumab + ipilimumab HML: > 199 and < 1000
TMB-H: 15 – 39 (TSO500) or 11 – 24 (Oncomine pane)
Olaparib ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD50, RAD51B, RAD51C, RAD51D, RAD54L
Panitumumab RAF/RAS wildtype
Pembrolizumab HML
Regorafenib RET, KIT, FLT1, BRAF
Rucaparib BRCA1, BRCA2, RAD51C, RAD51D, PALB2
Sunitinib CSF1R, FGFR1, FGFR2, FGFR3, FLT3, KDR, FLT4, KIT, PDGFRa, PDGFRb, RET
Talazoparib ATM, ATR, FANCA, FANCC, FANCD2, FANCF, FANCM, RAD51, RAD51B, RAD54L, NBN, MRE11, BARD1, BRIP1, CHEK1, CHEK2, PALB2, PRA1, HRD signature
Trametinib MAP2K1 (MEK1), MAP2K2 (MEK2), MAP2K4, MAP3K1, NRAS, GNA11, GNAQ, GNAS, BRAF, NF1 (only gliomas)
Trastuzumab + pertuzumab HER2
Vemurafenib + cobimetinib BRAF
Vismodegib PTCH1

Overview opened cohorts

Drug Tumor type Target Status
Afatinib NSCLC NRG1 fusion Closed
Dabrafenib Glioblastoma BRAF V600 mut Open
Dabrafenib Urothelial BRAF V600 mut Open
Dabrafenib + trametinib Cholangio BRAF V600 mut Open
Dabrafenib + trametinib Glioblastoma BRAF V600 mut Open
Dabrafenib + trametinib Glioma (grade 3) BRAF V600 mut Open
Dabrafenib + trametinib Low grade glioma BRAF V600 mut Open
Dabrafenib + trametinib Mamma BRAF V600 mut Open
Dabrafenib + trametinib Neuroendocrine carcinoma colon BRAF V600 mut Open
Dabrafenib + trametinib NSCLC BRAF V600 mut Closed
Panitumumab (Uveal) melanoma BRAF-KRAS-NRAS wildtype Open
Panitumumab ACUP BRAF-KRAS-NRAS wildtype Open
Panitumumab Anal cancer BRAF-KRAS-NRAS wildtype Open
Panitumumab Carcinosarcoma uterus BRAF-KRAS-NRAS wildtype Open
Panitumumab Cervix BRAF-KRAS-NRAS wildtype Open
Panitumumab Glioblastoma BRAF-KRAS-NRAS wildtype Closed
Panitumumab Gynaecological SCC BRAF-KRAS-NRAS wildtype Open
Panitumumab HNSCC BRAF-KRAS-NRAS wildtype Open
Panitumumab Meningioma BRAF-KRAS-NRAS wildtype Open
Panitumumab NSCLC BRAF-KRAS-NRAS wildtype + EGFRmut/amp Open
Panitumumab Salivary duct BRAF-KRAS-NRAS wildtype Open
Panitumumab Sarcoma BRAF-KRAS-NRAS wildtype Open
Panitumumab Thyroid BRAF-KRAS-NRAS wildtype Open
Regorafenib Adenoid cystic carcinoma BRAF mut Open
Regorafenib Duodenal FLT1 amp Open
Regorafenib Esthesioneuroblastoma RET Open
Regorafenib Melanoma KIT mut Open
Regorafenib NSCLC RET Open
Regorafenib NSCLC RAF1 mut Open
Regorafenib Thymus KIT mut Open
Trametinib ACUP MAP3K1 mut Open
Trametinib Cervix MAP3K1 mut Open
Trametinib Cholangio MAP2K4 mut Open
Trametinib Colorectal MAP2K1 mut Open
Trametinib Colorectal MAP2K4 mut/loss Open
Trametinib Mamma MAP3K1 mut Open
Trametinib Mamma MAP2K4 mut/loss Open
Trametinib Neuroendocrine carcinoma MAP3K1 mut Open
Trametinib NSCLC MAP2K1 mut Open
Trametinib NSCLC NRAS mut Open
Trametinib Ovarian NRAS mut Open
Trametinib Ovarian MAP2K4 mut Open
Trametinib Thyroid NRAS mut Open
Trametinib Prostate MAP3K1 mut Open
Trametinib Pleiomorphic malignancy NRAS mut Open
Trametinib Melanocytic tumor GNA11 mut Open
Trametinib Prostate NRAS mut Open
Trametinib Astrocytoma BRAF fusion Open
Trametinib Glioneural tumor BRAF fusion Open
Trametinib Cholangio NRAS mut Open
Trametinib NSCLC BRAF fusion Open
Trametinib Pancreas BRAF fusion Open
Trametinib Pancreas MAP2K1 mut Open
Trametinib Stomach MAP2K1 mut Open
Trametinib Pancreas MAP2K4 loss Open
Trametinib Low grade glioma NF1 mut Open
Trametinib Yolk sac tumor NRAS mut Open
Trastuzumab + pertuzumab Adenoid cystic carcinoma HER2 mut Open
Trastuzumab + pertuzumab Biliary tract HER2 amp/mut Open
Trastuzumab + pertuzumab Cervix HER2 mut Open
Trastuzumab + pertuzumab Cervix HER2 amp Open
Trastuzumab + pertuzumab Colorectal HER2 amp Open
Trastuzumab + pertuzumab Colorectal HER2 mut Open
Trastuzumab + pertuzumab Duodenal HER2 amp Open
Trastuzumab + pertuzumab Hidradenocarcinoma HER2 amp Open
Trastuzumab + pertuzumab Neuroendocrine carcinoma HER2 amp Open
Trastuzumab + pertuzumab NSCLC HER2 amp Open
Trastuzumab + pertuzumab NSCLC HER2 mut (exon 20) Closed
Trastuzumab + pertuzumab Ovarian HER2 mut Open
Trastuzumab + pertuzumab Ovarian HER2 amp Open
Trastuzumab + pertuzumab Salivary duct HER2 amp Open
Trastuzumab + pertuzumab Urinary tract HER2 amp Open
Trastuzumab + pertuzumab Urinary tract HER2 mut Open
Trastuzumab + pertuzumab Vulva HER2 amp Open
Vemurafenib + cobimetinib ACUP BRAF V600 mut Open
Vemurafenib + cobimetinib Erdheim Chester Disease BRAF V600 mut Open
Vemurafenib + cobimetinib NSCLC BRAF V600 mut Open
Vemurafenib + cobimetinib NSCLC BRAF non-V600 mut Open
Vemurafenib + cobimetinib Ovarian BRAF V600 mut Open
Vemurafenib + cobimetinib Papillary craniopharyngioma BRAF V600 mut Open
Vemurafenib + cobimetinib Salivary duct BRAF V600 mut Open
Vemurafenib + cobimetinib Thyroid BRAF V600 mut Open
Ribociclib Urothelial CDKN2A loss/mut Closed
Ribociclib Ceruminous adenocarcinoma CDKN2A loss/mut Closed
Ribociclib Ependymoma CDKN2A loss/mut Closed
Ribociclib Melanoma CDK4 amp Closed
Ribociclib ACUP CDKN2A loss/mut Closed
Ribociclib Prostate CDKN2A loss/mut Closed
Ribociclib Thymus CDKN2A loss/mut Closed
Ribociclib Sarcoma CDKN2A loss/mut Closed
Ribociclib Anaplastic meningioma CDKN2A loss/mut Closed
Ribociclib Salivary glands CDK6 amp Closed
Ribociclib Mesothelioma CDKN2A loss/mut Closed
Ribociclib Salivary glands CDKN2A loss/mut Closed
Alpelisib Miscellaneous tumor types PIK3CA mut Open
Alpelisib Upper GI-tumors PIK3CA mut Open
Vismodegib Sarcoma PTCH1 mut Open
Vismodegib Medulloblastoma PTCH1 mut Open
Erlotinib Glioblastoma EGFR mut Open
Erlotinib Glioblastoma EGFR fusion Open
Erlotinib Colorectal EGFR mut Open
Alectinib All tumor types ALK fusion Open
Nilotinib GIST KIT mut Open
Nilotinib GIST PDGFRa mut Open
Nilotinib Mesothelioma PDGFRa mut Open
Nilotinib Colorectal PDGFRb mut Open
Nilotinib Melanoma KIT mut Open
Lenvatinib Colorectal FGFR1 mut Open
Lenvatinib Cholangio FGFR2 fusion Open
Lenvatinib Cholangio FGFR3 fusion Open
Lenvatinib Biliary tract FGFR2 mut Open
Lenvatinib Glioblastoma FGFR2 fusion Open
Lenvatinib Colorectal FGFR2 amp Open
Lenvatinib Mamma FGFR2 amp/mut Open
Lenvatinib Mamma FGFR1 amp Open
Lenvatinib Osteosarcoma FGFR1 amp Open
Lenvatinib NSCLC FGFR1 amp Open
Lenvatinib NSCLC FGFR2 amp Open
Lenvatinib Anal cancer FGFR3 mut Open
Lenvatinib Endometrial FGFR2 mut Open
Lenvatinib Esophageal FGFR2 amp Open
Lenvatinib Salivary glands FGFR3 amp Open
Lenvatinib Neuroendocrine tumor (nasal cavity) FGFR3 amp Open
Lenvatinib ACUP FGFR2 fusion Open
Lenvatinib Urachus carcinoma FGFR2 amp Open
Lenvatinib HNSCC FGFR3 mut Open
Lenvatinib Urothelial FGFR3 mut Open
Lenvatinib Adenoid cystic carcinoma FGFR2 mut Open
Lenvatinib Salivary duct FGFR2 mut Open
Lenvatinib Glioneural tumor FGFR1 mut Open
Lenvatinib Pancreas FGFR2 fusion Open
Lenvatinib Digital papillary carcinoma FGFR2 mut Open
Sunitinib Thymus KIT mut Open
Sunitinib Prostate PDGFRa mut Open
Sunitinib Osteosarcoma PDGFRb mut Open
Sunitinib Urothelial FGFR1 amp Open
Sunitinib Mamma PDGFRb amp Open
Sunitinib Adenoid cystic carcinoma PDGFRa amp Open
Sunitinib Thyroid PDGFRa amp Open
Sunitinib Ovarian FGFR1 amp Open
Sunitinib Colorectal CSF1R mut Open
Sunitinib Colorectal FLT3 amp Open
Sunitinib NSCLC KIT amp Open
Sunitinib Ovarian FGFR2 amp Open
Crizotinib Inflammatory Myofibroblastic tumor ALK fusion Open
Crizotinib Colorectal MET amp Open
Crizotinib Colorectal ALK mut Open
Crizotinib Esophageal MET amp Open
Crizotinib NSCLC MET mut On hold
Crizotinib NSCLC MET amp Open
Crizotinib Thyroid ALK Open
Crizotinib Sarcoma ALK Open
Crizotinib CUP ALK fusion Open
Crizotinib Thyroid MET fusion Open
Crizotinib HCC MET amp Open
Crizotinib Gastro-esophageal junction MET amp Open
Cabozantinib Melanoma MET amp Closed
Cabozantinib Teratoma MET amp Closed
Cabozantinib NSCLC RET fusion/mut Closed
Cabozantinib GIST NTRK2 mut Closed
Cabozantinib Esophageal MET mut Closed
Palbociclib Colorectal CDKN2A loss/mut Closed
Palbociclib Glioblastoma CDKN2A loss/mut Closed
Palbociclib Cholangio CDKN2A loss/mut Closed
Palbociclib Melanoma CDKN2A loss/mut Closed
Palbociclib Uveal melanoma CDKN2A loss/mut Closed
Palbociclib PEComa CDKN2A loss/mut Closed
Palbociclib Small intestine CDKN2A loss/mut Closed
Palbociclib NSCLC CCND1 amp Closed
Palbociclib Ovarian CDKN2A loss/mut Closed
Palbociclib Ovarian SMARCA4 mut Closed
Palbociclib Vulva CDKN2A loss/mut Closed
Palbociclib Prostate CDK6 amp Closed
Palbociclib Melanoma CCND1 amp Closed
Palbociclib Colorectal SMARCA4 mut Closed
Palbociclib Renal clear cell CDKN2A loss/mut Closed
Palbociclib Esophageal CDK4 amp Closed
Palbociclib HNSCC CDKN2A loss/mut Closed
Palbociclib Primitive Neuro-ectodermal tumor CDKN2A loss/mut Closed
Palbociclib Carcinoid/Neuroendocrine tumor CCND1 amp Closed
Palbociclib Pancreas CDKN2A loss/mut Closed
Palbociclib Esophageal CDKN2A loss/mut Closed
Palbociclib NSCLC CDKN2A loss/mut Closed
Palbociclib Sarcoma CDK4 amp Closed
Palbociclib Astrocytoma CDK4 amp Closed
Palbociclib Colorectal CCND2 amp Closed
Palbociclib Prostate CDK4 amp Closed
Axitinib Colorectal FLT1 amp Open
Abemaciclib Urothelial CCND1 amp Open
Abemaciclib NSCLC CCND1 amp Open
Abemaciclib Prostate CCND1 amp Open
Abemaciclib Melanoma CCND1 amp Open
Abemaciclib Small intestine CCND3 amp Open
Durvalumab All tumor types MSI-H Closed
Olaparib All tumor types BRCA1/2 mut/loss Closed
Olaparib All tumor types ATM mut/loss Open
Olaparib Mamma, ovarian, prostate, pancreas, SCLC, stomach HRR alteraions Open
Olaparib All other tumor types HRR alteraions Open
Rucaparib Mamma BRCA1/2, RAD51C, RAD51D and PALB2 Open
Rucaparib Ovarian BRCA1/2, RAD51C, RAD51D and PALB2 Open
Rucaparib Prostate BRCA1/2, RAD51C, RAD51D and PALB2 Open
Rucaparib Pancreas BRCA1/2, RAD51C, RAD51D and PALB2 Open
Rucaparib All other tumor types BRCA1/2, RAD51C, RAD51D and PALB2 Open
Talazoparib All tumor types HRD signature Open
Nivolumab + ipilimumab All tumor types HML (200 – 1000)/ H-TMB Open
Nivolumab All tumor types MSI-H Open
Nivolumab All tumor types HML (> 450) Closed
Pembrolizumab Colorectal HML (140 – 290) Closed
Pembrolizumab Esophageal / Cardia / Stomach HML (140 – 290) Closed
Pembrolizumab HNSCC HML (140 – 290) Open
Pembrolizumab Prostate HML (140 – 290) Open
Pembrolizumab Mamma HML (140 – 290) Open
Pembrolizumab Miscellaneous tumor types HML (140 – 290) On hold
Pembrolizumab All tumor types HML > 290 On hold